Neurology Book

http://www.fpnotebook.com/

RopiniroleAka: Requip

Advertisement

  1. Indications
    1. Parkinson's Disease
    2. Restless Leg Syndrome
  2. Dosing: Restless Leg Syndrome
    1. Start: Requip 0.25 mg orally taken 2-3 hours before bedtime
    2. Interval for increasing dose: 3-7 days
    3. Titrating dose: Increase at set interval as above by one tablet if ineffective at current dose
      1. Start at 0.25 mg one tablet nightly for set interval in days
      2. Increase to two tablets (0.50 mg) nightly for set interval if ineffective at 0.25 mg
      3. Increase to three tablets (0.75 mg) nightly for set interval if ineffective at 0.50 mg
    4. Maximum dose: 6 tablets (1.5 mg) taken at bedtime
    5. Stopping: No titration needed
  3. Adverse Effects (similar to Mirapex)
    1. Nausea (common)
    2. Drowsiness (Limited to higher dosages)
      1. May be sudden, severe without warning
      2. May occur up to one year after starting Mirapex
      3. Has resulted in falling asleep while driving
    3. Augmentation of Restless Leg Symptoms
      1. Occurs in 25% of RLS patients on longterm therapy
      2. May progress in severity, and involve arms, trunk
      3. Often better if dose timing changed to earlier in day
      4. May be worse if dose increased
    4. Other uncommon adverse effects (rare at low dose)
      1. Hallucinations
      2. Pathologic Gambling (related to Dopamine receptor agonist activity, D3)
      3. Orthostatic Hypotension
      4. Hypersexuality

ropinirole (C0244821)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
Englishropinirol, ropinirole, ROPINIROLE PREPARATION
Spanishropinirol, ropinirola
CreditsDerived from the NIH UMLS (Unified Medical Language System)


Requip (C0593342)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
EnglishGlaxoSmithKline brand of ropinirole hydrochloride, Requip, SmithKline Beecham brand of ropinirole hydrochloride
CreditsDerived from the NIH UMLS (Unified Medical Language System)



Navigation Tree